DOCSLIB.ORG

MGUS) and Monoclonal B- Cell Lymphocytosis (MBL

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MGUS) and Monoclonal B- Cell Lymphocytosis (MBL Open access Original research BMJ Open: first published as 10.1136/bmjopen-2020-041296 on 22 February 2021. Downloaded from Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B- cell lymphocytosis (MBL): findings from a UK population-based cohort Maxine JE Lamb ,1 Alexandra Smith ,1 Daniel Painter ,1 Eleanor Kane ,1 Timothy Bagguley ,1 Robert Newton ,1,2 Debra Howell ,1 Gordon Cook,3 Ruth de Tute,4 Andrew Rawstron,4 Russell Patmore,5 Eve Roman 1 To cite: Lamb MJE, Smith A, ABSTRACT Strengths and limitations of this study Painter D, et al. Health impact Objective To examine mortality and morbidity patterns of monoclonal gammopathy before and after premalignancy diagnosis in individuals of undetermined significance ► Data are from an established population- based co- with monoclonal gammopathy of undetermined (MGUS) and monoclonal B- hort within which all haematological malignancies significance (MGUS) and monoclonal B-cell lymphocytosis cell lymphocytosis (MBL): and related clonal disorders are diagnosed, moni- findings from a UK population- (MBL) and compare their secondary healthcare activity to tored and coded at a single laboratory. that of the general population. based cohort. BMJ Open ► Providing nationally generalisable data, all diagnoses 2021;11:e041296. doi:10.1136/ Design Population- based patient cohort, within which are included, and complete follow- up is achieved via bmjopen-2020-041296 each patient is matched at diagnosis to 10 age- matched linkage to nationwide administrative datasets. and sex- matched individuals from the general population. ► Prepublication history for ► The age- matched and sex-ma tched general popula- this paper is available online. Both cohorts are linked to nationwide information tion cohort enables baseline activity and rate ratios To view these files, please visit on deaths, cancer registrations and Hospital Episode to be calculated, both before and after premalignan- the journal online (http:// dx. doi. Statistics. cy detection. org/ 10. 1136/ bmjopen- 2020- Setting The UK’s Haematological Malignancy Research ► Analyses are constrained by the fact that hospital 041296). Network, which has a catchment population of around 4 episodes statistics are primarily collected for admin- http://bmjopen.bmj.com/ million served by 14 hospitals and a central diagnostic Received 04 June 2020 istrative and clinical purposes and not for research. laboratory. Revised 20 January 2021 Accepted 22 January 2021 Participants All patients newly diagnosed during 2009– 2015 with MGUS (n=2193) or MBL (n=561) and their age and sex-ma tched comparators (n=27 538). systemic disease resulting in wide- ranging organ/tissue Main outcome measures Mortality and hospital inpatient damage and excess mortality. and outpatient activity in the 5 years before and 3 years after diagnosis. Results Individuals with MGUS experienced excess BACKGROUND on September 24, 2021 by guest. Protected copyright. morbidity in the 5 years before diagnosis and excess Monoclonal gammopathy of undetermined mortality and morbidity in the 3 years after diagnosis. significance (MGUS) and monoclonal B-cell Increased rate ratios (RRs) were evident for nearly all lymphocytosis (MBL) are premalignant clinical specialties, the largest, both before and after monoclonal B- cell disorders, the former diagnosis, being for nephrology (before RR=4.29, 95% progressing to myeloma at a rate of around CI 3.90 to 4.71; after RR=13.8, 95% CI 12.8 to 15.0) and 1% per year1 2 and the latter to chronic rheumatology (before RR=3.40, 95% CI 3.18 to 3.63; after lymphocytic leukaemia (CLL) at around RR=5.44, 95% CI 5.08 to 5.83). Strong effects were also 2% per year.3 4 Diagnosed more frequently evident for endocrinology, neurology, dermatology and in men than women and people over 60 © Author(s) (or their respiratory medicine. Conversely, only marginal increases 5 6 employer(s)) 2021. Re- use in mortality and morbidity were evident for MBL. years of age, overt symptoms of haemato- permitted under CC BY. Conclusions MGUS and MBL are generally considered logical malignancy are, by definition, absent Published by BMJ. 7 to be relatively benign, since most individuals with in both MBL and MGUS. Accordingly, For numbered affiliations see monoclonal immunoglobulins never develop a B-cell although some premalignant disorders are end of article. malignancy or any other monoclonal protein-rela ted found coincidentally during routine health Correspondence to organ/tissue-rela ted disorder. Nonetheless, our findings checks, others are identified during diag- Professor Eve Roman; offer strong support for the view that in some individuals, nostic work- up investigations; MGUS during eve. roman@ york. ac. uk monoclonal gammopathy has the potential to cause the course of tests applied to detect a range Lamb MJE, et al. BMJ Open 2021;11:e041296. doi:10.1136/bmjopen-2020-041296 1 Open access BMJ Open: first published as 10.1136/bmjopen-2020-041296 on 22 February 2021. Downloaded from of potential conditions and illnesses8 9 and MBL during made during 2009–2015, MBL was defined by a periph- episodes of unexplained lymphocytosis.4 10 eral blood monoclonal B- cell count <5×109/L in individ- In addition to the association with haematological uals with no other features of a B-cell lymphoproliferative malignancy, individuals with MGUS or MBL sometimes disorder, in MGUS by a serum paraprotein less than 30 experience higher than expected levels of mortality and g/L and in those where a bone marrow examination was morbidity that are independent of cancer.4 8 11–16 Indeed, considered necessary following clinical examination, a although most individuals with these disorders suffer clonal bone marrow plasma cells/lymphoplasmacytic no obvious ill effects, interest in their relationship with infiltration of less than 10%. Hence, within the HMRN other comorbidities has increased markedly in recent region, as in other diagnostic settings,21 22 invasive bone years, MBL largely in relation to its potential to impact on marrow examinations in patients with MGUS are gener- the immune response17 and MGUS due to the systemic ally only carried when laboratory or clinical features organ and tissue damage that can be caused by mono- are indicative of an underlying plasma cell neoplasm, clonal immunoglobulins secreted by the abnormal B- cell lymphoproliferative disorder, monoclonal immunoglob- clone.18 Hitherto, however, most information about these ulin deposition disease (eg, amyloidosis) or conditions associations has been derived either from case–control like polyneuropathy, organomegaly, endocrinopathy, studies established to look at risk factors for disease devel- monoclonal gammopathy and skin changes (POEMS) opment (eg, family history of disease) and additional syndrome.7 tests applied to specific patient groups (eg, patients with To facilitate comparisons with unaffected individuals, kidney disease) or cohort studies that track individuals HMRN also has a general population cohort. To create with either MGUS or MBL forwards in time from their this ‘control’ cohort, all patients diagnosed during 2009– diagnosis.5 13 18 However, despite the undoubted interest 2015 with a haematological malignancy or related clonal in the sequence of health events, as far as we are aware, no disorder (n=18 127) were individually matched on sex systematic population- based investigations of the comor- and age at the point of diagnosis to 10 randomly selected bidity patterns that precede and succeed a diagnosis of individuals from the same catchment population. All either MGUS or MBL have been undertaken in the same controls were assigned a serial number that linked them cohort. to their matched case and a ‘pseudodiagnosis’ date that With a view to shedding light on the health events corresponded to their matched case’s diagnosis date. occurring before and after the diagnosis of MGUS and Individuals in the patient cohort and the comparison MBL, the present report uses data from an established UK cohort are linked to the same nationwide information on population- based patient cohort of haematological malig- deaths, cancer registrations and Hospital Episode Statis- nancies and related disorders to examine the comorbidity tics (HES). At the point of selection and matching, all patterns of individuals with these premalignancy clonal controls were resident in the HMRN region and none disorders (MGUS=2193, MBL=561). To enable effect had a previous cancer registration for a haematological http://bmjopen.bmj.com/ size quantification, these patterns are compared with the malignancy.23 24 Hence, for the control cohort (in contrast baseline activity of an individually age- matched and sex- to the patient cohort) no additional health information matched (10 per patient) general population comparison outside that contained within national administrative cohort. datasets was available. Using similar methods to those previously described,23–25 associations with hospital inpatient activity (HES admitted METHODS patient care) and outpatient activity (HES outpatient Cases are from the Haematological Malignancy Research (HES- OP)) in the 5 years prior to diagnosis/pseudodiag- on September 24, 2021 by guest. Protected copyright. Network (HMRN; www. HMRN. org), a specialist UK nosis through to the 3 years after diagnosis were investi- registry established in 2004 to provide robust generalis- gated. HES inpatient data contain ICD-10 codes derived able data to inform contemporary clinical practice
Load more

Recommended publications
  • Noninfectious Mixed Cryoglobulinaemic Glomerulonephritis and Monoclonal Gammopathy of Undetermined Significance: a Coincidental Association? Adam L
    Flavell et al. BMC Nephrology (2020) 21:293 https://doi.org/10.1186/s12882-020-01941-3 CASE REPORT Open Access Noninfectious mixed cryoglobulinaemic glomerulonephritis and monoclonal gammopathy of undetermined significance: a coincidental association? Adam L. Flavell1* , Robert O. Fullinfaw2, Edward R. Smith1,3, Stephen G. Holt1,3, Moira J. Finlay3,4 and Thomas D. Barbour1,3 Abstract Background: Cryoglobulins are cold-precipitable immunoglobulins that may cause systemic vasculitis including cryoglobulinaemic glomerulonephritis (CGN). Type 1 cryoglobulins consist of isolated monoclonal immunoglobulin (mIg), whereas mixed cryoglobulins are typically immune complexes comprising either monoclonal (type 2) or polyclonal (type 3) Ig with rheumatoid activity against polyclonal IgG. Only CGN related to type 1 cryoglobulins has been clearly associated with monoclonal gammopathy of undetermined significance (MGUS) using the conventional serum-, urine- or tissue-based methods of paraprotein detection. Case presentation: We present four patients with noninfectious mixed (type 2 or 3) CGN and MGUS. Two patients had type 2 cryoglobulinaemia, one had type 3 cryoglobulinaemia, and one lacked definitive typing of the serum cryoprecipitate. The serum monoclonal band was IgM-κ in all four cases. Treatments included corticosteroids, cyclophosphamide, plasma exchange, and rituximab. At median 3.5 years’ follow-up, no patient had developed a haematological malignancy or advanced chronic kidney disease. Other potential causes of mixed cryoglobulinaemia were also present in our cohort, notably primary Sjögren’s syndrome in three cases. Conclusion: Our study raises questions regarding the current designation of type 2 CGN as a monoclonal gammopathy of renal significance, and the role of clonally directed therapies for noninfectious mixed CGN outside the setting of haematological malignancy.
    [Show full text]
  • Cardiac Nonamyloidotic Immunoglobulin Deposition Disease
    Modern Pathology (2006) 19, 233–237 & 2006 USCAP, Inc All rights reserved 0893-3952/06 $30.00 www.modernpathology.org Cardiac nonamyloidotic immunoglobulin deposition disease Amir A Toor1,6, Ben A Ramdane1, Jacob Joseph2, Maria Thomas3, Carl O’Hara4, Bart Barlogie1, Patrick Walker5 and Lija Joseph3,4,7 1Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; 2Division of Cardiovascular Medicine, Boston University School of Medicine, Boston, MA, USA; 3Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA; 4Department of Pathology, Mallory Institute of Pathology, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA and 5Nephropathology Associates, Little Rock, AR, USA Cardiac nonamyloidotic immunoglobulin (Ig) deposition disease (CIDD) is a rare disorder characterized by Ig deposition in the myocardium associated with plasma cell dyscrasias. A retrospective review of cardiac biopsies performed at two different institutions identified eight patients with CIDD. All patients had plasma cell dyscrasias with monoclonal gammopathy. Three had IgG k, two had IgG j, one had IgD j and one each had free j and free k light chain. Four patients had concurrent amyloidosis involving other organs. One had amyloidosis of kidney alone, one had amyloidosis of kidney and abdominal fat pad and two others had amyloidosis of bone marrow vasculature. Three patients had dialysis-dependent renal insufficiency. None of the patients had symptoms of heart failure. Six patients had echocardiographically demonstrable concentric left ventricular hypertrophy with diastolic dysfunction. Two patients had significant cardiac arrhythmias requiring medical intervention. On endomyocardial biopsy, all eight had normal appearing myocardium on light microscopy with negative Congo Red and Thioflavin T stains.
    [Show full text]
  • Waldenstrom's Macroglobulinemia
    Review Article Open Acc Blood Res Trans J Volume 3 Issue 1 - May 2019 Copyright © All rights are reserved by Mostafa Fahmy Fouad Tawfeq DOI: 10.19080/OABTJ.2019.02.555603 Waldenstrom’s Macroglobulinemia: An In-depth Review Sabry A Allah Shoeib1, Essam Abd El Mohsen2, Mohamed A Abdelhafez1, Heba Y Elkholy1 and Mostafa F Fouad3* 1Internal Medicine Department , Faculty of Medicine, Menoufia University 2El Maadi Armed Forces Institute, Egypt 3Specialist of Internal Medicine at Qeft Teatching Hospital, Qena, Egypt Submission: March 14, 2019; Published: May 20, 2019 *Corresponding author: Mostafa Fahmy Fouad Tawfeq MBBCh, Adress: Elzaferia, Qeft, Qena, Egypt Abstract Objective: The aim of the work was to through in-depth lights on new updates in waldenstrom macroglobulinemia disease. Data sources: Data were obtained from medical textbooks, medical journals, and medical websites, which had updated with the key word (waldenstrom macroglobulinemia ) in the title of the papers. Study selection: Selection was carried out by supervisors for studying waldenstrom macroglobulinemia disease. Data extraction: Special search was carried out for the key word waldenstrom macroglobulinemia in the title of the papers, and extraction was made, including assessment of quality and validity of papers that met with the prior criteria described in the review. Data synthesis: The main result of the review and each study was reviewed independently. The obtained data were translated into a new language based on the need of the researcher and have been presented in various sections throughout the article. Recent Findings: We now know every updated information about Wald Enstrom macroglobulinemia and clinical trials. A complete understanding of the Wald Enstrom macroglobulinemia will be helpful for the future development of innovative therapies for the treatment of the disease and its complications.
    [Show full text]
  • Progression of a Solitary, Malignant Cutaneous Plasma-Cell Tumour to Multiple Myeloma in a Cat
    Case Report Progression of a solitary, malignant cutaneous plasma-cell tumour to multiple myeloma in a cat A. Radhakrishnan1, R. E. Risbon1, R. T. Patel1, B. Ruiz2 and C. A. Clifford3 1 Mathew J. Ryan Veterinary Hospital of the University of Pennsylvania, Philadelphia, PA, USA 2 Antech Diagnostics, Farmingdale, NY, USA 3 Red Bank Veterinary Hospital, Red Bank, NJ, USA Abstract An 11-year-old male domestic shorthair cat was examined because of a soft-tissue mass on the left tarsus previously diagnosed as a malignant extramedullary plasmacytoma. Findings of further diagnostic tests carried out to evaluate the patient for multiple myeloma were negative. Five Keywords hyperproteinaemia, months later, the cat developed clinical evidence of multiple myeloma based on positive Bence monoclonal gammopathy, Jones proteinuria, monoclonal gammopathy and circulating atypical plasma cells. This case multiple myeloma, pancytopenia, represents an unusual presentation for this disease and documents progression of an plasmacytoma extramedullary plasmacytoma to multiple myeloma in the cat. Introduction naemia, although it also can occur with IgG or IgA Plasma-cell neoplasms are rare in companion ani- hypersecretion (Matus & Leifer, 1985; Dorfman & mals. They represent less than 1% of all tumours in Dimski, 1992). Clinical signs of hyperviscosity dogs and are even less common in cats (Weber & include coagulopathy, neurologic signs (dementia Tebeau, 1998). Diseases represented in this category and ataxia), dilated retinal vessels, retinal haemor- of neoplasia include multiple myeloma (MM), rhage or detachment, and cardiomyopathy immunoglobulin M (IgM) macroglobulinaemia (Dorfman & Dimski, 1992; Forrester et al., 1992). and solitary plasmacytoma (Vail, 2001). These con- Coagulopathy can result from the M-component ditions can result in an excess secretion of Igs interfering with the normal function of platelets or (paraproteins or M-component) which produce a clotting factors.
    [Show full text]
  • MGUS): Diagnosis, Predictors of Progression, and Monitoring a Pocket Guide for the Clinician
    Monoclonal Gammopathy of Undetermined Significance (MGUS): Diagnosis, Predictors of Progression, and Monitoring A Pocket Guide for the Clinician DISTRIBUTION Brea C. Lipe, MD University of Rochester Medical Center Robert A. Kyle, MD Mayo Clinic, Rochester, MN November 2016 Recommendations in this guide are based on Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) FORmultiple myeloma: International Myeloma Working Group consensus perspectives risk factors for progression and guidelines for monitoring and management1 and additional sources.2,3,4,5,6 NOT Disease Definition Test Comment Monoclonal Gammopathy of Undetermined Significance (MGUS) is an Quantitative (IgG, IgA and IgM) May be suggestive of a immunoglobulins plasma cell disorder. asymptomatic condition that is included in a spectrum of monoclonal plasma cell disorders (dyscrasias). MGUS is characterized by a Serum immunoglobulin free light chains monoclonal protein (M protein) < 3 g/dL (30 g/L) in the serum and (including the ratio) < 10% monoclonal plasma cells in the bone marrow and no evidence of end-organ damage (“CRAB”: hypercalcemia, renal insufficiency, anemia or Secondary Evaluation bone lesions), lymphoma, Waldenström macroglobulinemia, or light chain Patients should undergo bone marrow aspiration and biopsy, amyloidosis (AL). Smoldering multiple myeloma (SMM) also lies along this including FISH and skeletal survey in the presence of an M-protein spectrum of plasma cell disorders, is also asymptomatic and is defined with any of the following: as having an M protein ≥ 3 g/dL (30 g/L) and/or ≥ 10% monoclonal plasma cells in the bone marrow and no CRAB features. Patients with • End-organ damage with “CRAB” features including high risk SMM may be candidates for clinical trials.
    [Show full text]
  • I M M U N O L O G Y Core Notes
    II MM MM UU NN OO LL OO GG YY CCOORREE NNOOTTEESS MEDICAL IMMUNOLOGY 544 FALL 2011 Dr. George A. Gutman SCHOOL OF MEDICINE UNIVERSITY OF CALIFORNIA, IRVINE (Copyright) 2011 Regents of the University of California TABLE OF CONTENTS CHAPTER 1 INTRODUCTION...................................................................................... 3 CHAPTER 2 ANTIGEN/ANTIBODY INTERACTIONS ..............................................9 CHAPTER 3 ANTIBODY STRUCTURE I..................................................................17 CHAPTER 4 ANTIBODY STRUCTURE II.................................................................23 CHAPTER 5 COMPLEMENT...................................................................................... 33 CHAPTER 6 ANTIBODY GENETICS, ISOTYPES, ALLOTYPES, IDIOTYPES.....45 CHAPTER 7 CELLULAR BASIS OF ANTIBODY DIVERSITY: CLONAL SELECTION..................................................................53 CHAPTER 8 GENETIC BASIS OF ANTIBODY DIVERSITY...................................61 CHAPTER 9 IMMUNOGLOBULIN BIOSYNTHESIS ...............................................69 CHAPTER 10 BLOOD GROUPS: ABO AND Rh .........................................................77 CHAPTER 11 CELL-MEDIATED IMMUNITY AND MHC ........................................83 CHAPTER 12 CELL INTERACTIONS IN CELL MEDIATED IMMUNITY ..............91 CHAPTER 13 T-CELL/B-CELL COOPERATION IN HUMORAL IMMUNITY......105 CHAPTER 14 CELL SURFACE MARKERS OF T-CELLS, B-CELLS AND MACROPHAGES...............................................................111
    [Show full text]
  • Type-I Cryoglobulinaemia Associated to Monoclonal Gammapathy of Undetermined Significance
    194) Prague Medical Report / Vol. 121 (2020) No. 3, p. 194–199 Type-I Cryoglobulinaemia Associated to Monoclonal Gammapathy of Undetermined Significance Juan Manuel Duarte1, Paloma Ocampo1, Silvia Graciela Ramos2, Orlando Gabriel Carballo2, Ricardo E. Barcia1, Cecilia Elena Arévalo1 1Sexta Cátedra de Medicina Interna, Hospital de Clínicas “José de San Martín”, Universidad de Buenos Aires, Buenos Aires, Argentina; 2Laboratorio de Inmunología, Unidad de Inmunología e Histocompatibilidad, Hospital Carlos G. Durand, Gobierno de la Ciudad de Buenos Aires, Buenos Aires, Argentina Received December 20, 2019; Accepted September 14, 2020. Key words: Cryoglobulinaemia – Monoclonal gammopathy of undetermined significance – Neuropathy – Vasculitis Abstract: Cryoglobulins are immunoglobulins that undergo reversible precipitation at cold temperatures. Monoclonal type-I cryoglobulinaemia is the least frequent and is associated to hematological diseases such as multiple myeloma, Waldenström’s macroglobulinaemia, chronic lymphocytic leukaemia and lymphoma. We describe the case of a 60-year-old female patient, who suffered from burning pain in her feet for ten months before her admission. The patient presented intermittent distal cyanosis that progressed to digital ischaemia. She also reported paresthesia in her hands, difficulty in writing, and a 26-kg-weight loss. At the physical examination, it was identified livedo reticularis, palpable purpura, and painful ecchymotic lesions in her calves and feet. Moreover, peripheral pulses were palpable and symmetrical. It was observed an atrophy of the right first dorsal interosseous and both extensor digitorum brevis, as well as a distal bilateral apalesthesia and allodynia. Both Achilles reflexes were absent. Laboratory tests revealed anemia, high erythrosedimentation rate and C-reactive protein. Serum protein electrophoresis showed a monoclonal IgG-Kappa gammopathy.
    [Show full text]
  • Competition Between Clonal Plasma Cells and Normal Cells for Potentially
    Leukemia (2011) 25, 697–706 & 2011 Macmillan Publishers Limited All rights reserved 0887-6924/11 www.nature.com/leu ORIGINAL ARTICLE Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma B Paiva1,2,MPe´rez-Andre´s2,3, M-B Vı´driales1,2, J Almeida2,3, N de las Heras4, M-V Mateos1,2,LLo´pez-Corral1,2, NC Gutie´rrez1,2, J Blanco1, A Oriol5, MT Herna´ndez6, F de Arriba7, AG de Coca8, M-J Terol9, J de la Rubia10, Y Gonza´lez11, A Martı´n12, A Sureda13, M Schmidt-Hieber2,3, A Schmitz14, HE Johnsen14, J-J Lahuerta15, J Blade´16, JF San-Miguel1,2 and A Orfao2,3 on behalf of the GEM (Grupo Espan˜ol de MM)/PETHEMA (Programa para el Estudio de la Terape´utica en Hemopatı´as Malignas) cooperative study groups and the Myeloma Stem Cell Network (MSCNET) 1Servicio de Hematologı´a, Hospital Universitario de Salamanca, Salamanca, Spain; 2Servicio de Hematologia, Centro de Investigacio´n del Ca´ncer (CIC, IBMCC USAL-CSIC), Salamanca, Spain; 3Servicio General de Citometrı´a and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain; 4Servicio de Hematologı´a, Complejo Hospitalario de Leo´n, Leo´n, Spain; 5Servicio de Hematologı´a, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 6Servicio de Hematologı´a, Hospital Universitario de Canarias, Tenerife, Spain; 7Servicio de Hematologı´a, Hospital Morales Meseguer, Murcia, Spain; 8Servicio de Hematologı´a, Hospital Clı´nico Universitario de Valladolid,
    [Show full text]
  • Neuropathy in Waldenstrom Macrogolubinemia B
    NEUROPATHY IN WALDENSTROM MACROGOLUBINEMIA B. JANE DISTAD, MD ASSOCIATE PROFESSOR DEPARTMENT OF NEUROLOGY JANUARY 13, 2018 OUTLINE • Anatomy • Epidemiology • Types • Pathophysiology • Investigation • Treatment DEFINITION - NEUROPATHY • a condition that develops from disease or damage to the peripheral nervous system — the vast network that transmits information between the central nervous system (the brain and spinal cord) and every other part of the body.– [NINDS NIH] • Symptoms - numbness or tingling, pricking sensations (paresthesia) or weakness. • burning pain (especially at night), muscle wasting • Peripheral (or distal) refers to the areas furthest from the body or core MOTOR PATHWAYS https://medatrio.com/ascending-descending-tracts-of-spinal-cord/ PAIN AND TEMPERATURE PATHWAYS POSITION SENSE AND BALANCE PATHWAYS Imagequiz.co.uk ORIGIN OF THE PERIPHERAL NERVE Spinal cord •From: The Importance of Rare Subtypes in Diagnosis and Copyright © 2015 American Medical Treatment of Peripheral Neuropathy A Review JAMA Neurol. Association. All rights reserved. 2015;72(12):1510-1518. doi:10.1001/jamaneurol.2015.2347 EPIDEMIOLOGY • Precision limited given multiple different definitions & causes & reporting • Peripheral neuropathy affects at least 20 million people in the United States • Neuropathy is reported in 50% of patients with diabetes mellitus • Guillain Barre Syndrome1.5 cases/100,000/year, for example • Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) affects 5 people in every 100,000 (if population of Seattle is 800,000,
    [Show full text]
  • A Case of Monoclonal Gammopathy in Extranodal Marginal Zone B-Cell Lymphoma of the Small Intestine
    Korean J Lab Med 2011;31:18-21 Case Report DOI 10.3343/kjlm.2011.31.1.18 Diagnostic Hematology KJLM A Case of Monoclonal Gammopathy in Extranodal Marginal Zone B-cell Lymphoma of the Small Intestine Do Yeun Kim, M.D.1, Yong-Seok Kim, M.D.1, Hee Jin Huh, M.D.2, Jong Sun Choi, M.D. 3, Jeong Seok Yeo, M.D.4, Beom Seok Kwak, M.D.5, and Seok Lae Chae, M.D.2 Departments of Internal Medicine1, Laboratory Medicine2, Pathology3, Nuclear Medicine4, and Surgery5, College of Medicine, Dongguk University Ilsan Hospital, Goyang, Korea Monoclonal gammopathy occurs in one-third of the patients with mucosa-associated lymphoid tissue lymphoma (MALT lympho- ma). However, monoclonal gammopathy has been rarely reported in Korea. Paraprotenemia accompanying MALT lymphoma is strongly correlated with involvement of the bone marrow, and this involvement leads to the progression of the disease. Here, we present a case of a 66-yr-old man diagnosed with IgM monoclonal gammopathy and stage IV extranodal marginal zone lympho- ma of the small intestine, with the involvement of the bone marrow. (Korean J Lab Med 2011;31:18-21) Key Words: Marginal zone B-cell lymphoma, Monoclonal gammopathy, Bone marrow INTRODUCTION tive of advanced stages of the disease [8]. In Korea, monoclonal gammopathy in MALT lymphoma Extranodal marginal zone B-cell lymphoma (ENMZL) of has been rarely reported until recently [9]. Here, we report the mucosa-associated lymphoid tissue (MALT) accounts a case of a 66-yr-old man diagnosed with IgM monoclonal for 7–8% of all newly diagnosed B-cell lymphomas [1].
    [Show full text]
  • (MGUS) and Monoclonal B-Cell Lymphocytosis (MBL), Both Before and After Premalignancy Diagnosis; and Compare Their Activity to That of the General Population
    medRxiv preprint doi: https://doi.org/10.1101/2020.05.30.20117549; this version posted May 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort Corresponding author: Eve Roman, Epidemiology & Cancer Statistics Group, Department of Health Sciences, Seebohm Rowntree Building, University of York, YO10 5DX, UK: [email protected] Maxine Lamb1, Alexandra G Smith1, Daniel Painter1, Eleanor Kane1, Tim Bagguley1, Robert Newton1,2, Debra Howell1, Gordon Cook3, Ruth de Tute4, Andrew Rawstron4, Russell Patmore5, Eve Roman1 1 Department of Health Sciences, University of York, YO10 5DD, UK 2 Ugandan Virus Research Institute, Entebbe, Uganda 3 Department of Haematology, Leeds Cancer Centre, St James’s University Hospital, LS9 7LP, UK 4 Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, St James’s University Hospital, LS9 7LP, UK 5 Queens Centre for Oncology and Haematology, Hull University Teaching Hospitals NHS Trust, HU16 5JQ, UK NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2020.05.30.20117549; this version posted May 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • S Clone in Igm-MGUS and Waldenstro¨M’S Macroglobulinemia: New Criteria for Differential Diagnosis and Risk Stratification
    Leukemia (2014) 28, 166–173 & 2014 Macmillan Publishers Limited All rights reserved 0887-6924/14 www.nature.com/leu ORIGINAL ARTICLE Multiparameter flow cytometry for the identification of the Waldenstro¨m’s clone in IgM-MGUS and Waldenstro¨m’s Macroglobulinemia: new criteria for differential diagnosis and risk stratification B Paiva1,2, MC Montes1, R Garcı´a-Sanz1,2, EM Ocio1,2, J Alonso1, N de las Heras3, F Escalante3, R Cuello4, AG de Coca4, J Galende5, J Herna´ndez6, M Sierra7, A Martin1, E Pardal8,ABa´rez9, J Alonso10, L Suarez11, TJ Gonza´lez-Lo´ pez12, JJ Perez1, A Orfao2,13, M-B Vidrı´ales1,2 and JF San Miguel1,2 Although multiparameter flow cytometry (MFC) has demonstrated clinical relevance in monoclonal gammopathy of undetermined significance (MGUS)/myeloma, immunophenotypic studies on the full spectrum of Waldenstro¨m’s Macroglobulinemia (WM) remain scanty. Herein, a comprehensive MFC analysis on bone marrow samples from 244 newly diagnosed patients with an immunoglobulin M (IgM) monoclonal protein was performed, including 67 IgM-MGUS, 77 smoldering and 100 symptomatic WM. Our results show a progressive increase on the number and light-chain-isotype-positive B-cells from IgM-MGUS to smoldering and symptomatic WM (Po.001), with only 1% of IgM-MGUS patients showing 410% B cells or 100% light-chain-isotype-positive B-cells (Po.001). Complete light-chain restriction of the B-cell compartment was an independent prognostic factor for time-to progression in smoldering WM (median 26 months; HR: 19.8, P ¼ 0.001) and overall survival in symptomatic WM (median 44 months; HR: 2.6, P ¼ 0.004).
    [Show full text]